Additionally, a multicenter, randomized, phase III clinical trial involving breast cancer patients undergoing myelosuppressive chemotherapy found that mecapegfilgrastim exhibited comparable efficacy and even outperformed short‐acting G‐CSF (filgrastim) in reducing the occurrence and duration of severe neutropenia.17 The gene discussed is CSF3; the disease is Decreased total neutrophil count.